Sentences with phrase «u.s. drug prices»

A bit later, Trump detoured into an portion of the speech on the pharmaceutical industry, declaring the «injustice» of high U.S. drug prices as one of his «top priorities for the year.»

Politicians may pressure them to lower U.S. drug prices, but the stocks already reflect this risk.

The pharmaceutical industry is typically reluctant to talk about U.S. drug prices, generally the highest in the world due to a combination of market fragmentation and free market policies.

While some responders had particular axes to grind (it's true that U.S. drug prices are radically higher than elsewhere in the world, for instance, and maybe a gamma ray burst could destroy earth, but those aren't really things you can act on tomorrow), many more offered healthful reality checks that most of us could benefit from, including:

Here's yet another facet of the U.S. drug pricing conundrum: older treatments which have been around for years can win label expansions that significantly increase their value, and consequently, their list prices.

Not exact matches

Shkreli's basic modus operandi in the biopharma sphere was to take niche drugs in treatment spaces where U.S. patients have few options (although those medicines may very well have been approved and available in other countries) and bring them to market, after which he'd maintain carte blanche on the products» prices.

Price, who has presented his own replacement plan, is now turning to a job of managing a massive agency that oversees the U.S. Food and Drug Administration, Medicare, Medicaid, the Children's Health Insurance Program and other programs, and will be tasked with implementing what Congress ultimately sends him, Childs said.

With its traditional insulin treatments in the firing line due to U.S. price pressure, Novo Nordisk is pinning hopes for growth on new obesity drugs and a once - weekly injection and tablet version of its semaglutide drug.

But before his arrest, he said he'd use KaloBios as a vehicle to nab another niche drug, this time for treatment of the parasitic infection Chagas disease, and dramatically increase its price to the $ 60,000 to $ 100,000 range after helping it win FDA approval (the drug is approved in other countries and is provided to patients in the U.S. on a special and selective basis).

Activist hedge fund investor and recent Valeant Pharmaceuticals (vrx) board appointee Bill Ackman on Wednesday slammed the company's steep drug price hikes in testimony before the U.S. Senate Special Committee on Aging, going so far as to say the cost bumps «contributed to healthcare inflation and called into question the company's commitment to the patients it serves.»

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

The U.S. filed its first charges in a generic drug price - fixing probe on Wednesday, according to a report.

It is also under investigation by the U.S. Securities and Exchange Commission, U.S. Attorney's offices in Massachusetts and New York, as well as Congress, as part of their probes into price hikes for certain drugs.

Another bright spot could be the slowing in the decline of U.S. generic drug prices, according to report from Credit Suisse, citing data from health information company IQVIA.

Saunders has openly argued that pharma can head off more stringent drug price regulation in the U.S. (such as Trump's suggestions of competitive bidding and direct negotiations in Medicare) by self - policing.

At the end of the day, drug makers are allowed to price their products however they want to in the U.S. Barring some of the regulatory reforms that Trump has previously proposed but have an extremely rocky path through a GOP - controlled Congress, it's difficult to see the more subtle price hike dynamic change.

On the heels of rival diabetes drug maker Novo Nordisk's announcement that it will limit branded drug price hikes to the single digits going forward, U.S. pharma giant Eli Lilly announced Tuesday that it is partnering with benefits manager Express Scripts and a mobile health platform hosted by Blink Health to slash patients» insulin costs.

The companies have begun to market their «biosimilar» (a generic version of expensive biologic drugs) of Remicade — a copycat of J&J's best - selling rheumatoid arthritis and immunology treatment (which garnered more than $ 5 billion in U.S. sales last year) and was approved by the Food and Drug Administration (FDA) in April — at a striking 35 % discount to its list price.

U.S. drugmaker Turing Pharmaceuticals, led at the time by hedge fund manager Martin Shkreli, caused outrage last year by raising the U.S. price of Daraprim, an old anti-infective drug, by more than 5,000 % to $ 750 a pill.

The drug, given over four injections, costs $ 120,000 in the U.S. Bristol defends Yervoy's price tag, saying it reflects the survival benefit and the steep cost of the drug's development.

The president followed up later in the day, tweeting that Merck «is a leader in higher & higher drug prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES!&prices while at the same time taking jobs out of the U.S. Bring jobs back & LOWER PRICES!&PRICES!»

As well, if the U.S. government takes on the responsibility for buying drugs, it may force better pricing terms on producers, which could hurt revenues.

The April 26 memo comes just one day before three of Valeant's top executives are slated to appear before a different U.S. Senate panel that is also investigating high drug prices.

That reality would seem to suggest that the U.S. should adopt a system similar to those in other countries, which more tightly regulate drug prices and where the government largely subsidizes health care costs (as opposed to employers largely doing so in the U.S.) through what's known as a single - payer system.

Novo announced in September that Sørensen will be stepping down early after 16 years at the helm in the face of intense drug pricing scrutiny in the U.S., which has ravaged Novo's share price since its December 2015 peak.

By bringing a drug that's been well - established as safe in other markets to the U.S. for the first time in order to treat a rare disease, the company doesn't just control its pricing destiny — it will also receive a coveted «priority review voucher» which it can hawk to another firm for tens (or even hundreds) of millions of dollars.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SDrug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the Sdrug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Since biosimilars are so new to the U.S. market (there have been just five total approved here since 2015), it's been hard to gauge whether or not they can make a formidable dent in high drug prices by offering generic alternatives to branded treatments.

Drugmakers have benefitted from the surge of opioid - related deaths in the U.S.; last year, Bloomberg reported that the drug's price had risen tenfold in recent years, with state and local governments shelling out to make the med more widely available.

Months after Valeant Pharmaceuticals International Inc. said it would make discounts available to U.S. hospitals for two high - priced heart drugs, some medical centers say they have yet to see a cent of savings.

U.S. Food and Drug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns on Wall Street over efforts to curb drug pricDrug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health insurers should remain protected by federal law, sparking new concerns on Wall Street over efforts to curb drug pricdrug pricing.

WASHINGTON (Reuters)- U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for «Kabuki drug - pricing constructs» that profit the industry at the expense of consumDrug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for «Kabuki drug - pricing constructs» that profit the industry at the expense of consumdrug - pricing constructs» that profit the industry at the expense of consumers.

If Issue 2, or the Drug Price Relief Act, passes, the act would require the state and state agencies, including Ohio Medicaid, to pay the same or lower prices for prescription drugs as the U.S. Department of Veterans Affairs does.

Issue 2, or the Drug Price Relief Act, would require Ohio to pay no more for prescription drugs than the U.S. Department of Veterans Affairs.

House Democrats have started what they called an «in - depth» investigation into the pricing of drugs for neurological condition multiple sclerosis, the latest attempt by U.S. politicians to pressure manufacturers to lower costs.

Trump lashed out quickly at Frazier on Twitter after the announcement, accusing the drugmaker of being «a leader in higher & higher drug prices while at the same time taking jobs out of the U.S.»

Grocery stores run in contrast with the drug store wine market in the U.S., where customers are primarily motivated by a wine's price point and packaging and are typically shopping for the lowest - priced products.

In the U.S. some generic drugs have an inflated price because they are monopolized by one company.

In a statement, the Sanders campaign said TPC «wildly overestimates the cost of Senator Sanders» health care plan,» saying that the center «underestimates the savings in administration, paperwork, and prescription drug prices» that the U.S. might realize under Sanders» plan.

Students more likely to participate in free - and reduced - price lunch programs are among the same populations most likely to suffer from obesity and related health risks, said Janet Peckham, an economist in the Office of the Commissioner at the U.S. Food and Drug Administration and lead author of the study.

As it has for its HIV drugs, Gilead plans to provide patient assistance within the U.S., to license the drug (for a fee) to select generic manufacturers outside the U.S., and to lower prices in low - and middle - income countries.

Increasingly high prices for cancer drugs are affecting patient care in the U.S. and the American health care system overall, say the authors of a special article published online in the journal Mayo Clinic Proceedings.

Domestic U.S. prices for proprietary patented drugs are substantially higher than those in other developed nations.

The drug, given over four injections, costs $ 120,000 in the U.S. Bristol defends Yervoy's price tag, saying it reflects the survival benefit and the steep cost of the drug's development.

Some politicians have called for: Congressional hearings on the escalating pricing, an investigation by the Federal Trade Commission, and action by the U.S. Food and Drug Administration to increase competition by hastening approvals of competitors» products, the AP reported.

Washington, D.C. — December 17, 2014 --[GlobeNewswire]-- Weston A. Price Foundation filed a lawsuit today against the U.S. Food and Drug Administration (FDA) in the U.S. District Court for the District of Columbia.

The former is regulated by the U.S. Food and Drug Administration (FDA) and requires strict certification, which often explains the related price hike.

The round - up post shares a wealth of resources from the blog, and the associated podcast features Kevin Jennings, former assistant deputy secretary for the Office of Safe and Drug - Free Schools at the U.S. Department of Education; Penny Bisignano, Olweus coordinator for the Iowa Department of Education; and Rachel Cole Lawson, former high school counselor at Malcolm Price Laboratory School (the winner of the first - ever Vision in Action: The ASCD Whole Child Award) in Cedar Falls, Iowa

TOP DETRACTORS Portola Pharmaceuticals's stock price fell during the quarter after it received communications from the U.S. Food & Drug Administration (FDA) asking for additional information in the ongoing evaluation of its AndexXa drug, an antidote to commonly - prescribed blood thinners (factor Xa inhibitors) in patients who experience life threatening bleDrug Administration (FDA) asking for additional information in the ongoing evaluation of its AndexXa drug, an antidote to commonly - prescribed blood thinners (factor Xa inhibitors) in patients who experience life threatening bledrug, an antidote to commonly - prescribed blood thinners (factor Xa inhibitors) in patients who experience life threatening bleeds.

Currently represents a U.S. company in the Department of Justice's criminal investigation of price fixing of generic drugs